Безопасность и переносимость НПВС: фокус на ацеклофенак
https://doi.org/10.21518/2079-701X-2019-9-110-120
Аннотация
В статье обсуждаются основные проблемы безопасности нестероидных противовоспалительных средств (НПВС). Приводятся результаты рандомизированных клинических исследований, фармакоэпидемиологических исследований и метаанализов, предполагающие более высокую безопасность ацеклофенака по сравнению с диклофенаком и другими широко применяемыми НПВС. Особое внимание уделяется новой лекарственной форме ацеклофенака – таблеткам с модифицированным высвобождением, изготовленным по технологии Clanza, зарегистрированной под торговым наименованием Ацеклагин. Он предназначен для однократного введения в сутки, что позволяет повысить приверженность терапии.
Об авторах
Е. А. Ушкалова
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов».
Россия
Россия
д.м.н., профессор кафедры общей и клинической фармакологии Федерального государственного автономного образовательного учреждения высшего образования «Российский университет дружбы народов».
С. К. Зырянов
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов».
Россия
Россия
д.м.н., профессор, заведующий кафедрой общей и клинической фармакологией Федерального государственного автономного образовательного учреждения высшего образования «Российский университет дружбы народов».
К. Э. Затолочина
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов».
Россия
Россия
к.м.н., ассистент кафедры общей и клинической фармакологии Федерального государственного автономного образовательного учреждения высшего образования «Российский университет дружбы народов».
Список литературы
1. Conaghan P.G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International. 2012;32(6):1491-150. doi: 10.1007/s00296-011-2263-6.
2. Zhou Y., Boudreau D.M., Freedman A.N. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50. doi: 10.1002/pds.3463.
3. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594–606.
4. French D.P., James D.H. Reasons for the use of mild analgesics among English students. Pharm World Sci. 2008;30(1):79–85.
5. Stosic R., Dunagan F., Palmer H., et al. Responsible self-medication: perceived risks and benefits of over-the-counter analgesic use. Int J Pharm Pract. 2011;19(4):236–245.
6. Koffeman A.R., Valkhoff V.E., Celik S., W’t Jong G., Sturkenboom M.C., Bindels P.J., van der Lei J., Luijsterburg P.A., Bierma-Zeinstra S.M. High-risk use of over-the-counter non-steroidal antiinflammatory drugs: a population-based crosssectional study. Br J Gen Pract. 2014 Apr;64(621):e191-8. doi: 10.3399/bjgp14X677815.
7. Kasciuškevičiūtė S., Gumbrevičius G., Vendzelytė A., Ščiupokas A., Petrikonis K., Kaduševičius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti- Inflammatory Drug Use in Lithuania: An Observational Study. Medicina (Kaunas). 2018 May 11;54(2). pii: E30. doi: 10.3390/medicina54020030.
8. Kołodziejska J., Kołodziejczyk M. Diclofenac in the treatment of pain in patients with rheumatic diseases. Reumatologia. 2018;56(3):174-183. doi: 10.5114/reum.2018.76816.
9. Wilcox C.M., Cryer B., Triadafilopoulos G. Patterns of use and public perception of overthe- counter pain relievers: Focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32:2218-24.
10. French D.P., James D.H. Reasons for the use of mild analgesics among English students. Pharm World Sci. 2008;30(1):79–85.
11. Roberto G., Bartolini C., Rea F., Onder G., Vitale C., Trifirò G., Kirchmayer U., Chinellato A., Lucente- Forte E., Corrao G., Mugelli A., Lapi F., Gini R.; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. Eur J Clin Pharmacol. 2018 May;74(5):637-643. doi: 10.1007/s00228-018-2411-y.
12. Singh G., Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.
13. Pepine C.J., Gurbel P.A. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol. 2017 Dec;40(12):1352-1356. doi: 10.1002/clc.22814.
14. Schjerning Olsen A.M., Gislason G.H., McGettigan P., Fosbøl E., Sørensen R., Hansen ML., Køber L., Torp-Pedersen C., Lamberts M. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313:805–814. doi: 10.1001/jama.2015.0809.
15. Shin S.J., Noh C.K., Lim S.G., Lee K.M., Lee K.J. Non-steroidal anti-inflammatory drug-induced enteropathy. Intest Res. 2017 Oct;15(4):446-455. doi: 10.5217/ir.2017.15.4.446.
16. Wang R., Dasgupta A., Ward M.M. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi: 10.1136/annrheumdis-2015-207677.
17. van Walsem A., Pandhi S., Nixon R.M., Guyot P., Karabis A., Moore R.A. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase- 2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015;17:66. doi: 10.1186/s13075-015-0554-0.
18. Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin. 2012 Jan;28(1):163–78.
19. Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 2008;12(11):1–278.
20. Al Khaja K.A.J., Veeramuthu S., Isa H.A., Sequeira R.P. Prescription audit of NSAIDs and gastroprotective strategy in elderly in primary care. Int J Risk Saf Med. 2017;29(1-2):57-68. doi: 10.3233/JRS-170742.
21. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014 Oct;70(10):1159-72. doi: 10.1007/s00228-014-1734-6.
22. Karakitsiou M., Varga Z., Kriska M., Kristova V. Risk perception of NSAIDs in hospitalized patients in Greece. Bratisl Lek Listy. 2017;118(7):427-430. doi: 10.4149/BLL_2017_083.
23. Phueanpinit P., Pongwecharak J., Sumanont S., Krska J., Jarernsiripornkul N. Physicians’ communication of risks from non-steroidal anti-inflammatory drugs and attitude towards providing adverse drug reaction information to patients. J Eval Clin Pract. 2017 Dec;23(6):1387-1394. doi: 10.1111/jep.12806.
24. Hamilton K., Davis C., Falk J., Singer A., Bugden S. High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review. Int J Risk Saf Med. 2015;27(4):191-9. doi: 10.3233/JRS-150662.
25. McCarberg B.H., Cryer B. Evolving Therapeutic Strategies to Improve Nonsteroidal Antiinflammatory Drug Safety. Am J Ther. 2015 Nov- Dec;22(6):e167-78. doi: 10.1097/MJT.0000000000000123.
26. Davis A., Robson J. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016 Apr;66(645):172-3. doi: 10.3399/bjgp16X684433.
27. Crofford L.J. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3):S2. doi: 10.1186/ar4174.
28. Насонов Е.Л. Нестероидные противовоспали- тельные препараты в ревматологии. Лечащий врач. 2006;2. [Nasonov E.L. Non-steroidal antiinflammatory drugs in rheumatology. Lechashchij vrach. 2006;2.] (In Russ.)
29. Saad J., Pellegrini M.V. Nonsteroidal Anti- Inflammatory Drugs (NSAID) Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019-2019 Mar 2.
30. Oscanoa T.J., Lizaraso F., Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017 Jun;73(6):759-770. doi: 10.1007/s00228-017-2225-3.
31. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19.
32. Alexopoulou A., Dourakis S.P., Mantzoukis D., Pitsariotis T., Kandyli A., Deutsch M., Archimandritis A.J. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med. 2008 Nov;19(7):505-10. doi: 10.1016/j.ejim.2007.06.030.
33. Risser A., Donovan D., Heintzman J., Page T. NSAID prescribing precautions. Am Fam Physician. 2009 Dec 15;80(12):1371–8.
34. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.
35. Brune K., Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105-18. doi: 10.2147/JPR.S75160.
36. Masclee G.M., Valkhoff V.E., Coloma P.M., et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784–792.e9.
37. Straube S., Tramèr M.R., Moore R.A., Derry S., McQuay H.J. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41. doi: 10.1186/1471-230X-9-41.
38. Richy F., Bruyere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a metaanalytic approach. Ann Rheum Dis. 2004 Jul;63(7):759–66. doi: 10.1136/ard.2003.015925.
39. García Rodríguez L.A., Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001 Sep;12(5):570–6.
40. Massó González E.L., Patrignani P., Tacconelli S., García-Rodríguez L.A. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 2010;62:1592–1601.
41. Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C., Fourrier-Reglat A., Nicotra F., Sturkenboom M., Perez-Gutthann S.; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.
42. Degner F., Sigmund R., Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Ther. 2000;22(4):400–410.
43. Mann J.L., Evans T.S. Gastrointestinal-related complications in a long-term care population taking NSAIDs versus COX-2 inhibitor therapy. Consult Pharm. 2004 Jul;19(7):602–13.
44. Peterson K., McDonagh M., Thakurta S., et al. Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010 Nov. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53960.
45. Walker C., Biasucci L.M. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan;130(1):55-71. doi: 10.1080/00325481.2018.1412799.
46. US Food and Drug Administration. Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Drug Safety Communication – FDA Strengthens Warning of Increased Chance of Heart Attack or Stroke. July 9, 2015.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor-HumanMedicalProducts/ucm454141.htm.
47. Farkouh M.E., Greenberg B.P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103:1227–1237.
48. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 Sep;8(9):e1001098.
49. Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., et al. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 342:c7086. doi: 10.1136/bmj.c7086.
50. Bally M., Dendukuri N., Rich B., Nadeau L., Helin- Salmivaara A., Garbe E., Brophy J.M. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017 May 9;357:j1909. doi: 10.1136/bmj.j1909.
51. De Vecchis R., Baldi C., Di Biase G., Ariano C., Cioppa C., Giasi A., Valente L, Cantatrione S. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014 Dec;62(6):437-48.
52. Fosbøl E.L., Folke F., Jacobsen S., et al. Causespecific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010;3:395–405.
53. Kohli P., Steg P.G., Cannon C.P., et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014;127:53–60.
54. Olsen A.M., Fosbøl E.L., Lindhardsen J., et al. Longterm cardiovascular risk of nonsteroidal antiinflammatory drug use according to time passed after first-time myocardial infarction a nationwide cohort study. Circulation. 2012;126:1955–1963.
55. Ray W.A., Varas-Lorenzo C., Chung C.P., et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2:155–163.
56. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclooxygenase- 2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J. 2006;332:1302–1308. doi: 10.1136/bmj.332.7553.1302.
57. Bhala N., Emberson J., Merhi A., Abramson S., Arber N., Baron J.A., Bombardier C., Cannon C., Farkouh M.E., FitzGerald G.A., Goss P., Halls H., Hawk E., Hawkey C., Hennekens C., Hochberg M., Holland L.E., Kearney P.M., Laine L., Lanas A., Lance P., Laupacis A., Oates J., Patrono C., Schnitzer T.J., Solomon S., Tugwell P., Wilson K., Wittes J., Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013;382:769–779. doi: 10.1016/S0140-6736(13)60900-9.
58. Marsico F., Paolillo S., Filardi P.P. NSAIDs and cardiovascular risk. J Cardiovasc Med (Hagerstown). 2017 Jan;18(Suppl 1): Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation:e40-e43. doi: 10.2459/JCM.0000000000000443
59. Hernandez-Diaz S., Varas-Lorenzo C., Garcia Rodriguez L.A. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266–274.
60. Schjerning Olsen A.M., Fosbol E.L., Lindhardsen J., et al. Long-term cardiovascular risk of NSAID use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126:1955–1963.
61. Schmidt M., Lamberts M., Olsen A.M., Fosbøll E., Niessner A., Tamargo J., Rosano G., Agewall S., Kaski J.C., Kjeldsen K., Lewis B.S., Torp-Pedersen C. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardio vascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016 Apr 1;37(13):1015-23. doi: 10.1093/eurheartj/ehv505.
62. Unzueta A., Vargas H.E., Syed M., Skonberg C., Hansen S.H. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis. 2013 Nov;17(4):643-56, ix. doi: 10.1016/j.cld.2013.07.009.
63. Schmeltzer P.A., Kosinski A.S., Kleiner D.E., Hoofnagle J.H., Stolz A., Fontana R.J., Russo M.W.; Drug-Induced Liver Injury Network (DILIN). Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016 Apr;36(4):603-9. doi: 10.1111/liv.13032.
64. Teschke R. Top-ranking drugs out of 3312 druginduced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method Expert Opin Drug Metab Toxicol. 2018 Nov;14(11): 1169-1187. doi: 10.1080/17425255.2018.1539077.
65. Ramachandran A., Visschers R.G.J., Duan L., Akakpo J.Y., Jaeschke H. Mitochondrial toxicity of diclofenac and its metabolites via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria: Possible role in drug induced liver injury (DILI). Toxicol In Vitro. 2016 Mar;31:93-102. doi: 10.1016/j.tiv.2015.11.020.
66. Daly A.K., Aithal G.P., Leathart J.B. et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterol. 2007;132(1):272–281.
67. Krasniqi V., Dimovski A., Domjanović I.K., Bilić I., Božina N. How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada Toksikol. 2016 Mar;67(1):1-8. doi: 10.1515/aiht-2016-67-2754.
68. Kwon J., Kim S., Yoo H., Lee E. Nimesulideinduced hepatotoxicity: A systematic review and meta-analysis. PLoS One. 2019 Jan 24;14(1):e0209264. doi: 10.1371/journal.pone.0209264.
69. Donati M., Conforti A., Lenti M.C., Capuano A., Bortolami O., Motola D., Moretti U., Vannacci A., Rafaniello C., Vaccheri A., Arzenton E., Bonaiuti R., Sportiello L., Leone R.; DILI-IT Study Group. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi: 10.1111/bcp.12938.
70. EMA. Assessment report for Nimesulide containing medicinal products for systemic use: European Medicines Agency; [updated 2012 Apr 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf.
71. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.
72. Suh C.Y., Lee Y.J., Shin J.S., Lee J., Kim M.R., Koh W., Cha Y.Y., Shin B.C., Hwang E.H., Suhr K., Kim M., Ha I.H. Analysis of medical service use of knee osteoarthritis and knee meniscal and ligament injuries in Korea: a cross-sectional study of national patient sample data. BMC Musculoskelet Disord. 2017 Nov 10;18(1):438. doi: 10.1186/s12891-017-1795-7.
73. Dooley M., Spencer C.M., Dunn C.J. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.
74. Dingle J.T., Parker M. NSAID Stimulation of Human Cartilage Matrix Synthesis. A Study of the Mechanism of Action of Aceclofenac. Clin. Drug Invest. 1997;14:353-362. https://doi.org/10.2165/00044011-199714050-00003.
75. Насонова В.А. Ацеклофенак – безопасность и эффективность. РМЖ. 2003;11(5):3–6. [Nasonova V.A. Aceсlofenaс - safety and efficiency. RMZh. 2003;11(5):3–6.]
76. Vohra F., Raut A. Comparative efficacy, safety, and tolerability of diclofenac and aceclofenac in musculoskeletal pain management: A systematic review. Indian J Pain. 2016;30:3-6. doi: 10.4103/0970-5333.173431.
77. Patel P.B., Patel T.K. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-18. doi: 10.5152/eurjrheum.2017.160080.
78. Jung S.Y., Jang E.J., Nam S.W., Kwon H.H., Im S.G., Kim D., Cho S.K., Kim D., Sung Y.K. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network metaanalysis. Mod Rheumatol. 2018 Nov;28(6):1021-1028. doi: 10.1080/14397595.2018.1439694.
79. Peris F., Bird H.A., Srni U., Irani M.S., Diaz C., Gijon- Banos J. Treatment compliance and safety of aceclofenac versus standart NSAIDs in patients with common arthritis disorders: a meta-analysis. Eur J Rheum Inflamm. 1996;16(1):37-45.
80. Yanagawa A., Endo T., Kusakari K., Kudo T., Shimada J. and Mizushima Y. Endoscopic Evaluation of Aceclofenac-Induced Gastroduodenal Mucosal Damage: A Double- Blind Comparison with Sodium Diclofenac and Placebo. The Journal of Rheumatology. 1998;8:249-259. http://dx.doi.org/10.3109/BF03041246/
81. Wassif W., Bjarnason I. A comparison of the effects of aceclofenac and diclofenac on gastrointestinal blood loss. Br J Clin Research. 1992;3:109-1.
82. Pareek A., Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double- blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013 Jul;29(7):849-59. doi: 10.1185/03007995.2013.795139.
83. Huskinsson E.C., Irani M., Murray F. A large prospective open–label, multi–centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Europ. J. Rheumatol. Inflam. 2000;17:1–7.
84. Llorente Melero M.J., Tenías Burillo J.M., Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig. 2002 Jan;94(1):7-18.
85. Helin-Salmivaara A., Virtanen A., Veslainen R., Grönroos J.M., Klaukka T., Idänpään-Heikkilä J.E., Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart. 2006;27:1657–63. doi: 10.1093/eurheartj/ehl053.
86. Каратеев А.Е., Денисов Л.Н., Маркелова Е.И., Гукасян Д.А., Демидова Н.В., Касумова К.А., Насонов Е.Л. Результаты клинического исследования АЭРОПЛАН (анализ эффективности и риска осложнений при лечении артрита ацеклофенаком и нимесулидом). Consilium medicum. 2013;2:52-57. [Karateev A.E., Denisov L.N., Markelova E.I., Gukasyan D.A., Demidova N.V., Kasumova K.A., Nasonov E.L. Results of AEROPLAN clinical study (analysis of efficacy and risk of complications in the treatment of arthritis using aceclofenac and nimesulide). Consilium medicum. 2013;2:52-57.] (In Russ.)
87. Череватенко Р.Ф. Роль ацеклофенака (Аэртала) в комплексном лечении неспецифической люмбалгии. Хирургия. 2018;12:96-99. [Cherevatenko R.F. The role of aceclofenac (Airtal) in the complex treatment of nonspecific lumbodynia. Hirurgiya. 2018;12:96-99.] (In Russ.)
88. Lapeyre-Mestre M., Grolleau S., Montastruc J.L. Association Française des Centres Régionaux de Pharmacovigilance (CRPV Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol. 2013 Apr;27(2):223-30. doi: 10.1111/j.1472-8206.2011.00991.x.
89. Raber A., Heras J., Costa J., Fortea J., Cobos A. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag. 2007 Jun;3(2):225-30.
90. Dingle J.T. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol. 1999 Jun;58(3):125-9.
91. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000 Dec;131(7):1413-21.
92. Lemmel E.M., Leeb B., De Bast J., Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53.
93. de Klerk E., van der Heijde D., Landewé R., van der Tempel H., Urquhart J., van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003 Jan;30(1):44-54.
94. Coleman C.I., Limone B., Sobieraj D.M., Lee S., Roberts M.S., Kaur R., Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012 Sep;18(7):527-39.
95. Lee V.W., Pang K.K., Hui K.C., Kwok J.C., Leung S.L., Yu D.S., Lee D.T. Medication adherence: is it a hidden drug-related problem in hidden elderly? Geriatr Gerontol Int. 2013;13:978-985. doi: 10.1111/ggi.12042.
96. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296-310.
97. Bae S.K., Kim S.H., Lee H.W., Seong S.J., Shin S.Y., Lee S.H., Lim M.S., Yoon Y.R., Lee H.J. Pharmacokinetics of a new once-daily controlled- release formulation of aceclofenac in Korean healthy subjects compared with immediate- release aceclofenac and the effect of food: a randomized, open-label, three-period, crossover, single-centre study. Clin Drug Investig. 2012 Feb 1;32(2):111-9. doi: 10.2165/11596530-000000000-00000.
98. Инструкция к препарату Ацеклагин®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=31c2b7d0-8aa4-44ff-81f9-5aca2fdad03b&t, 22.05.2019. [Instructions forAceсlagin®. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=31c2b7d0-8aa4-44ff-81f9- 5aca2fdad03b&t, 22.05.2019.] (In Russ.)
99. Pareek A., Chandurkar N., Gupta A., Sirsikar A., Dalal B., Jesalpura B., Mehrotra A., Mukherjee A. Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain. 2011 May;12(5):546–53.
100. Jae-Ho Yang, Kyung-Soo Suk, Byung-Ho Lee, Woo- Chul Jung, Young-Mi Kang, Ji-Hye Kim, Hak- Sun Kim, Hwan-Mo Lee, Seong-Hwan Moon. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Med J. 2017 May; 58 (3): 637–643.
101. Moon Y.W., Kang S.B., Kim T.K., Lee M.C. Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. Knee Surg Relat Res. 2014 Mar;26(1):33-42.
102. Yang J.H., Suk K.S., Lee B.H., Jung W.C., Kang Y.M., Kim J.H., Kim H.S., Lee H.M., Moon S.H. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Med J. 2017 May;58(3):637-64.
103. Каратеев А.Е., Цурган А.В. Ацеклофенак: опыт российских исследований. Современная рев- матология. 2017;11(4):89–94. [Karateev A.E., Tsurgan A.V. Aceclofenac: Russian research experience. Sovremennaya revmatologiya. 2017;11(4):89–94.] (In Russ.)
104. Каратеев А.Е., Погожева Е.Ю., Филатова Е.С. Может ли ацеклофенак рассматриваться в качестве современного преемника «золотого стандарта» НПВП диклофенака. Обзор российских данных. Медицинский совет. 2018;1:98–103. [Karateev A.E., Pogozheva E.Yu., Filatova E.S. Whether aceclofenac can be considered as a modern receiver of the «gold standard» of diclofenac NSAID. Review of Russian data. Medicinskij sovet. 2018;1:98–103.] (In Russ.)
Рецензия
Для цитирования:
Ушкалова ЕА, Зырянов СК, Затолочина КЭ. Безопасность и переносимость НПВС: фокус на ацеклофенак. Медицинский Совет. 2019;(9):110-120. https://doi.org/10.21518/2079-701X-2019-9-110-120
For citation:
Ushkalova EA, Zyryanov SK, Zalolochina KE. Safety and tolerability of nsaids: focus on aceclofenac. Meditsinskiy sovet = Medical Council. 2019;(9):110-120. (In Russ.) https://doi.org/10.21518/2079-701X-2019-9-110-120
Просмотров: 841
Послать статью по эл. почте 